<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166442">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840098</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-63-13</org_study_id>
    <nct_id>NCT01840098</nct_id>
  </id_info>
  <brief_title>Leucine and Beta-hydroxy-beta-methylbutyrate (HMB) as Anabolic Nutrients After 36 Hours of Fasting</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate metabolic effects of 3 different nutritional
      compounds.

      Fasting (36 hours) creates a catabolic state that is comparable with the catabolic state
      seen in acute illness.

      This study is a randomized, placebo cross-over study investigating 8 healthy men on 4
      separated days (at least 3 weeks between trials).

        -  High leucine content drink

        -  Low leucine content drink

        -  Low leucine content drink + HMB

        -  Carbohydrate (isocaloric)

      The investigators hypothesize that these nutritional supplements may counteract catabolic
      processes in different ways and degrees.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Protein metabolism after 36 hours fasting receiving different nutritional supplements.</measure>
    <time_frame>3 control period followed by 4 hours of nutritional drink intake</time_frame>
    <safety_issue>No</safety_issue>
    <description>Protein metabolism is measured with amino acid tracer techniques comparing marked amino acids from blood samples. Muscle and fat biopsies are obtained for signaling analysis. Indirect calorimetry measurements are used to compare metabolism in the control period and during the intervention.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Fasting</condition>
  <condition>Metabolism</condition>
  <condition>Nutrition Support</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isocaloric carbohydrate drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low leucine content drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A soy protein drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high content of leucine drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A whey protein drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low leucine content + HMB drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Soy protein drink added HMB</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>low leucine content drink</intervention_name>
    <arm_group_label>low leucine content drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>high leucine content drink</intervention_name>
    <arm_group_label>high content of leucine drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>low leucine + HMB drink</intervention_name>
    <arm_group_label>low leucine content + HMB drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control/carbohydrate</intervention_name>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>36 hour fasting</intervention_name>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>low leucine content drink</arm_group_label>
    <arm_group_label>high content of leucine drink</arm_group_label>
    <arm_group_label>low leucine content + HMB drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male gender

          -  20&lt;BMI&lt;30

          -  Age &gt; 25 years old

          -  Written consent before starting the study

        Exclusion Criteria:

          -  Allergy for soya products ore egg

          -  Diabetes

          -  Epilepsy

          -  Infection

          -  Immune defects

          -  Heart disease

          -  Dysregulated hypertension

          -  Participating in other trials using radioactive tracers or x-rays the last year.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nikolaj F. Rittig, MD</last_name>
    <phone>+75 61714731</phone>
    <email>nikolaj.rittig@ki.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Internal Medicine and Endocrinology, Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaj Rittig, MD</last_name>
      <phone>+45 78462071</phone>
      <email>nikolaj.rittig@ki.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Nikolaj Fibiger Rittig</investigator_full_name>
    <investigator_title>MD (medical graduate) and Ph.d.-student</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
